Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + Binimetinib in BRAFV600-mutant NSCLC
NCT03915951Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of encorafenib, binimetinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Jun 2019; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03915951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915951.